Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study
Status: Recruiting
Location: See all (63) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Male or female (sex at birth).
• Age 18-75 years (both inclusive) at the time of signing the informed consent.
• Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as assessed by central laboratory at screening.
• Willingness to obtain a high weight loss (greater than \[\>\] 25% of weight at baseline).
Locations
United States
California
First Valley Medical Group
RECRUITING
Lancaster
Torrance Clinical Research Institute, Inc.
RECRUITING
Lomita
Ark Clinical Research
RECRUITING
Long Beach
Pacific Clinical Studies
RECRUITING
Los Alamitos
Wetlin Research Associates, Inc.
RECRUITING
San Diego
Diablo Clinical Research, Inc.
RECRUITING
Walnut Creek
Florida
Encore Medical Research LLC
RECRUITING
Hollywood
Bioclinical Research Alliance
RECRUITING
Miami
South Broward Research LLC
RECRUITING
Miramar
West Orange Endocrinology
NOT_YET_RECRUITING
Ocoee
Encore Medical Research of Weston
RECRUITING
Weston
Idaho
Elite Clinical Trials
RECRUITING
Blackfoot
Illinois
Cedar-Crosse Research Center
RECRUITING
Chicago
Massachusetts
Brigham & Women's Hospital
NOT_YET_RECRUITING
Boston
Missouri
Headlands Research
RECRUITING
Springfield
North Carolina
PharmQuest
RECRUITING
Greensboro
Piedmont Healthcare Statesville
RECRUITING
Statesville
Ohio
Providence Center for Clinical Research
RECRUITING
Dayton
Tennessee
CNS Healthcare
RECRUITING
Memphis
Texas
University of Texas Southwestern Medical Center
RECRUITING
Dallas
JCCT- Juno NW Houston
RECRUITING
Houston
Consano Clinical Research, LLC
RECRUITING
Shavano Park
West Virginia
Frontier Clinical Research - Kingwood
NOT_YET_RECRUITING
Kingwood
Other Locations
Croatia
Opca bolnica Karlovac
RECRUITING
Karlovac
Poliklinika SLAVONIJA OSIJEK
RECRUITING
Osijek
Opca bolnica Varazdin_Endocrinology
RECRUITING
Varaždin
Poliklinika Solmed
RECRUITING
Zagreb
Hungary
Debreceni Egyetem
NOT_YET_RECRUITING
Debrecen
Debreceni Egyetem
NOT_YET_RECRUITING
Debrecen
Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ
NOT_YET_RECRUITING
Szeged
Japan
Akaicho Clinic_Diabetes Internal Medicine
RECRUITING
Chiba-shi, Chiba
Naka Kinen Clinic_Internal medicine
RECRUITING
Ibaraki
Soka Sugiura Internal Medicine Clinic
RECRUITING
Soka-shi, Saitama
ToCROM Clinic_Internal Medicine
RECRUITING
Tokyo
Tokyo-Eki Center-building Clinic_Internal Medicine
RECRUITING
Tokyo
Poland
Zdrowie Osteo-Medic s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik
NOT_YET_RECRUITING
Bialystok
Terpa Sp. z o.o. Sp. k.
NOT_YET_RECRUITING
Lublin
Formed 2 Sp. z o.o.
RECRUITING
Oświęcim
PANSTWOWY INSTYTUT MEDYCZNY MSWiA
RECRUITING
Warsaw
Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Szyszko
RECRUITING
Zabrze
Portugal
Casa De Saúde De Santa Filomena S.A._Unidade de Ensaios Clínicos
RECRUITING
Coimbra
Cardiolima Centro Diagnostico Cardio-Pulmonar De Ponte De Lima Lda
RECRUITING
Ponte De Lima
Hospital Trofa Saude Senhor do Bonfim S.A_Unidade de Ensaios Clínicos
RECRUITING
Vila Do Conde
Hospital da Luz Arrábida, S.A_Serviço de Endocrinologia
RECRUITING
Vila Nova De Gaia
Republic of Korea
Korea University Ansan Hospital_Endocrinology
NOT_YET_RECRUITING
Ansan-si
Kangbuk Samsung Hospital_Endocrinology
NOT_YET_RECRUITING
Seoul
Nowon Eulji Medical Center, Eulji University_Endocrinology
NOT_YET_RECRUITING
Seoul
Pusan National University Yangsan Hospital
NOT_YET_RECRUITING
Yangsan
Slovakia
DIADA, s.r.o.
RECRUITING
Bardejov
Diacrin s. r. o.
RECRUITING
Bratislava
Metabol KLINIK s.r.o.
RECRUITING
Bratislava
SIN AZUCAR s.r.o.
RECRUITING
Malacky
Spain
Centro de Salud A Estrada
NOT_YET_RECRUITING
A Estrada
Equip D´Atencio Primaria Barcelona Sardenya
RECRUITING
Barcelona
Hospital Vithas Sevilla
RECRUITING
Castilleja De La Cuesta
Clínica Bofill
RECRUITING
Girona
ABS La Roca del Vallés_Endocrinología
RECRUITING
La Roca Del Vallés
Centro de Saúde Concepción Arenal
NOT_YET_RECRUITING
Santiago De Compostela
Thailand
Ramathibodi Hospital
NOT_YET_RECRUITING
Bangkok
Siriraj Hospital
NOT_YET_RECRUITING
Bangkok
Maharaj Nakorn Chiang Mai
NOT_YET_RECRUITING
Chiang Mai
Srinagarind Hospital
NOT_YET_RECRUITING
Khon Kaen
Maharat Nakhon Ratchasima Hospital
NOT_YET_RECRUITING
Nakhon Ratchasima
Contact Information
Primary
Novo Nordisk
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Time Frame
Start Date: 2026-04-17
Estimated Completion Date: 2027-10-01
Participants
Target number of participants: 270
Treatments
Experimental: NNC0662-0419
Participants will receive NNC0662-0419 subcutaneously (s.c.) in a dose escalating manner once weekly.
Active_comparator: Semaglutide
Participants will receive semaglutide s.c. once weekly.
Placebo_comparator: Placebo
Participants will receive placebo matched to their respective investigational medicinal product s.c. once weekly.
Related Therapeutic Areas
Sponsors
Leads: Novo Nordisk A/S